The objective of this study was to investigate the prevalence of pathogenic germline variants (PGVs) in 32 cancer susceptibility genes in individuals with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). A key secondary objective was to evaluate how often PGVs would have been undetected with existing genetic testing criteria. METHODS: From May 2016 through May 2017, this multicenter cohort study enrolled consecutive patients aged 18 to 89 years with histologically confirmed PDAC diagnosed within the previous 12 weeks. Demographics, medical histories, and 3-generation pedigrees were collected from participants who provided samples for germline DNA analysis. RESULTS: Four hundred nineteen patients were deemed eligible, 302 were enrolled, and 298 were included in the final cohort. Clinically actionable variants were reported in 29 PDAC patients (9.7%), with 23 (7.7%) having a PGV associated with an increased risk for PDAC. Six of 23 individuals (26%) with PDAC-associated gene mutations did not meet currently established genetic testing criteria. According to guideline-based genetic testing, only 11 of the 23 PGVs (48%) in known PDAC genes would have been detected. Six additional patients (2%) had PGVs associated with an increased risk for other cancers. CONCLUSIONS: These findings support the significant prevalence of PGVs associated with PDAC and the limitations of current paradigms for selecting patients for genetic testing, and they thereby lend support for universal germline multigene genetic testing in this population.
INTRODUCTION
Pancreatic cancer is the third most common cause of cancer deaths in the United States, with more than 44,000 patients predicted to die of this disease in 2018.
1 Most patients present with advanced disease, and they have a 5-year survival rate of only 8%. 1 It is estimated that up to 10% of pancreatic ductal adenocarcinomas (PDACs) are hereditary. 2 Pathogenic germline variants (PGVs) in 13 genes are associated with an increased risk for PDAC development: BRCA1 and BRCA2 for hereditary breast and ovarian cancer (HBOC); cyclin-dependent kinase inhibitor 2A (CDKN2A) for familial atypical multiple mole melanoma syndrome (FAMMM); MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MutS homolog 6 (MSH6), PMS2, and epithelial cell adhesion molecule (EPCAM) for Lynch syndrome (LS); serine/threonine kinase 11 (STK11) for Peutz-Jeghers syndrome (PJS); adenomatous polyposis coli (APC) for familial adenomatous polyposis; TP53 for Li-Fraumeni syndrome; partner and localizer of BRCA2 (PALB2); and ataxia-telangiesctasia mutated (ATM). [3] [4] [5] In addition, patients with hereditary pancreatitis caused by PGVs in protease serine 1 (PRSS1) have a significant risk for pancreatic cancer. 6 In the era of precision medicine, knowing whether an individual has a genetic susceptibility to pancreatic cancer can be used to develop strategies for cancer prevention, early detection, and treatment. Surveillance is currently reserved for those at highest risk because of either a known hereditary cancer syndrome associated with PDAC or a family history consistent with familial pancreatic cancer (FPC), which is defined as a family with at least 2 first-degree relatives with PDAC. 7 Knowledge of the PGV status of individuals with PDAC allows for the identification of family members who should be considered for cancer surveillance and who may also benefit from prevention or risk-reduction strategies. Furthermore, those PDAC patients who have a PGV could be candidates for targeted therapy.
Recent retrospective studies from registries using multigene panels that included PDAC-associated and other cancer susceptibility genes reported germline mutations in 4% to 25% of patients with PDAC not selected for their family history. [8] [9] [10] [11] [12] These studies have drawn attention to the prevalence of a genetic predisposition to PDAC and to the limitations of current guidelines for genetic testing in patients with PDAC. However, differences in panel design and cohort ascertainment confound the determination of the true prevalence of mutations and the relative contributions of individual genes to PDAC susceptibility.
The primary aim of this prospective study was to estimate the prevalence of PGVs in 32 cancer susceptibility genes, including 13 PDAC-associated genes, in a population of consecutive patients with newly diagnosed PDAC unselected by family history. We also examined whether and to what extent PGVs would have been detected under current genetic testing criteria with 3-generation pedigrees obtained by genetic counselors.
MATERIALS AND METHODS

Participants
Participants consisted of consecutive, unselected adult patients with newly diagnosed, histologically confirmed PDAC presenting between May 2016 and May 2017 at the University of Pittsburgh Medical Center (Pittsburgh, Pennsylvania), the Beth Israel Deaconess Medical Center (Boston, Massachusetts), and HonorHealth (Scottsdale, Arizona). The patient eligibility criteria were an age of 18 to 89 years, PDAC diagnosed within 12 weeks of consideration for the study, and an ability to provide informed consent. Patients were enrolled consecutively by study staff at each site and were not preselected on the basis of family history, prior genetic testing, or a known hereditary syndrome. The study was approved by the institutional review board of each enrollment site.
Procedures
A blood or saliva sample was collected for genetic testing. Demographics, medical histories, and tumor characteristics were based on patient reports and available clinical records. A minimum 3-generation cancer-centered pedigree elicited by a genetic counselor at enrollment was reviewed to determine whether genetic evaluation or testing criteria were met for FPC, HBOC, LS, familial adenomatous polyposis, PJS, FAMMM, or Li-Fraumeni syndrome (Supporting Table 1 ). [13] [14] [15] [16] [17] [18] [19] Next-generation sequencing and a large deletion/ duplication analysis of a panel of 32 cancer susceptibility genes, which consisted of the 13 aforementioned genes known to be associated with a predisposition for PDAC and 19 genes shown to be associated with a risk for other cancers (BRCA1-associated RING domain 1 [20] [21] [22] PGVs refer to pathogenic and likely pathogenic variants identified.
Analogously to the methods of Mandelker et al, 10 a variant was considered clinically actionable on the basis of currently available surveillance, prevention, or treatment implications for any cancer in either the patient or his or her close family members. Inconclusive and negative results were combined into the noncarrier group (ie, not actionable).
Statistical Analysis
Patient characteristics were summarized as frequencies for categorical variables and as medians and interquartile ranges for continuous variables. Data available for patients who declined to participate in our study were limited to the age at diagnosis and sex; differences in age and sex between patients who did and did not participate were evaluated with a Wilcoxon rank sum test and Fisher's exact test, respectively. For all participating patients, PGV prevalence was assessed, and it was defined as the number of patients carrying a mutation divided by the total number of patients tested. With a sample size of 300 patients, our study was powered to detect a PGV prevalence of 10% with 3.4% precision (95% confidence interval, 6.6%-13.4%). Associations between test results and patient characteristics were assessed with Wilcoxon rank sum tests for continuous variables and with Fisher's exact test for categorical variables; P < .05 was considered statistically significant.
The number of PGVs that would have been undetected with existing criteria for genetic testing was assessed in 2 ways. The first assumed that if a patient met criteria for guideline-based genetic testing, a comprehensive multigene panel would be ordered, and thus all actionable mutations would be identified for patients meeting any testing guideline. The second approach assumed that only guideline-based testing would be performed (eg, only BRCA1 and BRCA2 genes would be tested in patients meeting HBOC criteria).
RESULTS
In total, 419 patients were eligible, and 72% (302 of 419) enrolled and underwent genetic testing. There was no difference in the median age or in the proportions of males and females between patients who did participate and patients who did not participate in our study (P 5 .50 and P 5 .44, respectively). Results were reported in a median of 17 days (interquartile range, 13-20 days). Four patients were removed from the data analysis because it was later established that they did not meet the study eligibility criteria: 1 who was older than 89 years and 3 who were determined to have another type of periampullary tumor after surgical resection.
The final study cohort consisted of 298 patients (Table 1 ). The median age was 68.5 years (interquartile range, 62-75 years), and the 2 sexes were nearly equally represented. Most patients were white (86%), and 9% were Ashkenazi Jews. In addition to PDAC, nearly 20% of the patients had a personal history of at least 1 other cancer, the most common being prostate cancer (13% of males), breast cancer (4%), and melanoma (2%). Approximately 70% of the patients had a first-degree relative with cancer, with approximately 8% having PDAC. Overall, 41% of the participants met at least 1 established genetic testing criterion: 34% for HBOC, 8% for FPC, and 8% for LS.
Twenty-nine clinically actionable variants were identified in 29 patients, and this yielded a prevalence of 9.7% (Table 2) . Twenty-three patients (7.7%) carried PGVs in genes known to be associated with an increased risk for PDAC. Six patients (2%) had PGVs in cancer susceptibility genes not previously recognized as related to PDAC. ATM was the most frequently mutated gene with a prevalence of 3.3%, and it was followed by BRCA1 and BRCA2 mutations combined, which were identified in 2.7% of the cohort. The frequency of mutation carriers did not differ among the enrollment sites (P 5 .91; Table  3 ). Thirteen PGVs with uncertain clinical actionability were identified (Supporting Table 2 ). Patients with inconclusive results (ie, variants of unknown significance) accounted for 23.5% (n 5 70) of all those tested. Participants carrying PGVs were more likely to have a personal history of 1 or more cancers (37.9% vs 17.5%; P 5 .013) and/or have at least 1 first-degree relative with cancer (89.7% vs 68.4%; P 5 .007), and they were more likely to meet at least 1 genetic testing criterion (72.4% vs 37.9%; P < .001) in comparison with noncarriers (Table  3) . PDAC stage and diagnosis age did not differ between PGV carriers and noncarriers (P 5 .58 and P 5 .64, respectively). Notably, 3 of the 10 ATM mutation carriers also had a personal history of melanoma.
Patients found to carry PGVs were more likely to have met HBOC testing criteria in comparison with patients in whom no mutation was identified (62.1% vs 30.5% for noncarriers; P 5 .001). Seven of the 10 CHEK2 mutation carriers and 5 of the 10 participants with ATM mutations met criteria for HBOC testing. PGV carriers were no more likely to have met FPC criteria than noncarriers (10.3% vs 7.8%; P 5 .72). Meeting LS criteria was not associated with carrying a PGV (6.9% vs 8.2%; P 5 1.00). One participant fulfilled Chompret's criteria and was found to carry a likely pathogenic TP53 variant. No patients met criteria for PJS. Two participants met testing criteria for FAMMM and did not have a CDKN2A PGV. The individual carrying a CDKN2A PGV did not meet FAMMM criteria. As shown in Table 2 , with strict guideline-based genetic testing, 11 of 23 PGVs (48%) in known PDAC genes would have been detected. Applying a multigene panel to any patient who met at least 1 testing criterion yielded a higher number of PDAC-related PGVs (17 of 23 [74%]). None of the PGVs in BARD1 (n 5 1), CHEK2 (n 5 10), or RAD50 (n 5 1) would have been detected with guideline-based testing because there are no existing criteria for performing genetic testing for these genes (Supporting Table 2 ).
DISCUSSION
Our prospective, multicenter study of germline testing in unselected, newly diagnosed PDAC patients with a 32-gene panel increased the detection of germline mutations beyond that predicted by clinical testing criteria. The frequency of any clinically actionable variant was 9.7%, and the majority (80%) were identified in PDAC-associated genes.
A previous study using a panel of 22 cancer susceptibility genes in 96 patients enrolled at the Mayo Clinic found an overall mutation frequency of 14%, with 9% in known PDAC-associated genes. 8 Recently, a high prevalence of germline mutations (19%) in exocrine pancreatic cancer was reported by Lowery et al. 23 However, 20% of the study population was Ashkenazi and accounted for one-third of the pathogenic mutations identified, which may have contributed to the high frequency of mutations. Shindo et al 11 evaluated 854 participants from Johns Hopkins Hospital and found only 3.9% (33 of 854) with a mutation in 1 of 32 cancer susceptibility genes evaluated, with 3.6% (31 of 854) in known PDAC susceptibility genes. Although our study was not sufficiently powered to detect the prevalence of individual rare genes, the frequency of mutations in genes such as BRCA1/2 was in the range of what has been previously reported for primarily non-Ashkenazi cohorts. 8, 12, 24 For example, we found that 2.7% of the patients (8 of 298) had mutations in BRCA1/2, whereas 1.8% of the patients (15 of 854) in the Hopkins cohort did, with both studies finding less than a 1% prevalence of mutations in PALB2 (1 of 298 and 2 of 854). Likewise, Lowery et al found that only 1 of 615 patients with pancreatic cancer had a germline mutation in PALB2.
The most frequent genes with PGVs in this study were ATM, BRCA1/2, and CHEK2. Although some studies in PDAC cohorts have not analyzed CHEK2, 9,25 the prevalence of germline CHEK2 mutations was approximately 4% (7 of 176) among patients with pancreatic cancer in the study by Mendelker et al. 10 Further studies are needed to clarify the risk for PDAC in individuals with germline CHEK2 PGVs. Most CHEK2 and ATM mutation carriers did meet criteria for HBOC testing, possibly because both genes are also breast cancer susceptibility genes. Although 3 of the 10 ATM mutation carriers had a personal history of melanoma, there is currently no known relation between germline ATM mutations and melanoma.
Our results add to existing evidence demonstrating the limitations of genetic testing criteria for identifying actionable mutations in cancer patients. 10, 26, 27 If adherence to clinical testing guidelines is a prerequisite for germline testing, patients with PDAC are among those with the highest prevalence of undetected actionable germline mutations. 10 According to our study, if each patient who meets any criteria for genetic testing is tested with this 32-gene panel, we would expect that 26% of actionable variants (6 of 23) would not be identified. More than half of the PGVs (12 of 23) would be missed if guideline-based testing were conducted, as often required by third-party payers. Therefore, our data support universal germline genetic testing with a multigene panel for patients with PDAC.
Knowledge of the germline mutation status for a patient with PDAC provides the opportunity for cascade testing so that relatives may use this information for cancer risk assessment, surveillance, and prevention. Other than mutations in BRCA1/2, mutations in ATM and CHEK2 were most common in our cohort. Identifying these mutations affords the opportunity for proactive surveillance for breast (ATM and CHEK2) and colon cancer (CHEK2) in at-risk family members and survivors of PDAC.
14 Likewise, the identification of MSH6 and CDKN2A mutation carriers in our study, neither of whom met syndrome-related criteria for genetic testing, allows surveillance for Lynch-related cancers and melanoma. Increasingly, the utility of germline testing for individuals with PDAC may extend beyond cancer risk prediction to treatment. Recently, retrospective studies have reported increased survival for PDAC patients with germline mutations in BRCA1/2 or PALB2 who received platinum chemotherapy. 12, 28 In addition, trials evaluating poly(adenosine diphosphate ribose) polymerase inhibitors in PDAC patients with germline mutations in BRCA1/2 or PALB2 are ongoing (National Cancer Institute 8993 and NCT03140670). Furthermore, with the recent Food and Drug Administration approval of the use of immune checkpoint inhibitors to treat advanced refractory tumors with microsatellite instability or mismatch repair deficiency, identifying germline mutations in mismatch repair genes may provide additional therapeutic options for patients with PDAC. 29 A major strength of our study is the prospective, multicenter study design by which newly diagnosed PDAC patients were enrolled with genetic test results reported in real time. Although incorporating genetic assessments by experts in cancer genetics into our study design renders our data related to the fulfillment of current testing criteria dependable, the routine use of genetic counselors in the initial care of patients with PDAC may not be feasible. The time and resources needed to collect a 3-generation pedigree and assess complex testing guidelines before testing may be better directed to posttest counseling after a universal approach to genetic testing. Our study design supports the feasibility of successfully integrating genetic testing into clinical management because genetic testing results from a Clinical Laboratory Improvement Amendments-approved laboratory were usually available within 3 weeks; this allowed for potential mutation-directed therapies. A limitation of the study is the inclusion of only tertiary referral centers; despite our efforts to address this by limiting participants to patients with newly diagnosed PDAC, such as would be seen at community hospitals, we did observe a higher proportion of patients with resectable-stage PDAC than expected. However, this is unlikely to have influenced our findings because there was no association between stage and positive genetic test results detected, with reasonable sample sizes in each group. Because 86% of the patients in the current study were white, future studies are needed to test the application of germline genetic testing in nonwhite populations of patients with PDAC.
Results from this prospective study, demonstrating that 9.7% of patients with PDAC have an actionable PGV in a cancer susceptibility gene, support the application of a multigene panel for germline genetic testing in patients with PDAC. Furthermore, if we assume that all studyeligible patients were negative for a germline mutation, our estimate of mutation prevalence remains notable at 7%.
Our study also demonstrates the feasibility of performing genetic testing at the time of diagnosis. The detection of clinically actionable mutations may inform therapeutic options as well as future cancer risks for family members. Some have raised the question whether universal germline genetic testing for patients with PDAC is optimal. 30, 31 Our findings confirm the limitations of current genetic testing criteria for identifying mutations in patients with PDAC and lend support for universal germline genetic testing in this population; this is analogous to the approach currently recommended for BRCA1 and BRCA2 testing in patients with epithelial ovarian cancer. 14 
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